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Background: The use of near-infrared (NIR) fluorescence imaging techniques has gained great interest for early
detection of cancer because water and other intrinsic biomolecules display negligible absorption or
autofluorescence in this region. Novel fluorescent nanoparticles with potential to improve neoplasm detection
sensitivity may prove to be a valuable tool in early detection of colon tumors.
Methods: The present study describes the synthesis and use of NIR fluorescent albumin nanoparticles as a
diagnostic tool for detection of colon cancer. These fluorescent nanoparticles were prepared by a precipitation
process of human serum albumin (HSA) in aqueous solution in the presence of a carboxylic acid derivative of the
NIR dye IR-783 (CANIR). Tumor-targeting ligands such as peanut agglutinin (PNA), anti-carcinoembryonic antigen
antibodies (anti-CEA) and tumor associated glycoprotein-72 monoclonal antibodies (anti-TAG-72) were covalently
conjugated to the albumin nanoparticles via the surface carboxylate groups by using the carbodiimide activation
method.
Results and discussion: Leakage of the encapsulated dye into PBS containing 4% HSA or human bowel juice was
not detected. This study also demonstrates that the encapsulation of the NIR fluorescent dye within the HSA
nanoparticles reduces the photobleaching of the dye significantly. Specific colon tumor detection in a mouse
model was demonstrated for PNA, anti-CEA and anti-TAG-72 conjugated NIR fluorescent HSA nanoparticles. These
bioactive NIR fluorescent albumin nanoparticles also detected invisible tumors that were revealed as pathological
only subsequent to histological analysis.
Conclusions: These results may suggest a significant advantage of NIR fluorescence imaging using NIR fluorescent
nanoparticles over regular colonoscopy. In future work we plan to broaden this study by encapsulating cancer
drugs, such as paclitaxel and doxorubicin, within these biodegradable NIR fluorescent HSA nanoparticles, in order to
use them for both detection as well as therapy of colon cancer and others.
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Early detection of adenomatous colonic polyps is a
major concern in the prevention of colon cancer [1,2].
Colorectal cancer can largely be prevented by the early
detection and removal of adenomatous polyps. A variety
of colorectal cancer screening modalities are available,
including stool-based tests and radiological and endo-
scopic examinations of the colon [3,4]. These methods* Correspondence: shlomo.margel.mail.biu.ac.il
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distribution, and reproduction in any mediumare considered to be either lacking in sensitivity or inva-
sive, and colon cancer continues to be a major cause of
death in the western world. Novel fluorescent nanoparti-
cles with potential to improve neoplasm detection sensi-
tivity may prove to be a valuable tool in early detection
of colon tumors.
The key to effective specific imaging in deep tissues is the
use of NIR light [5]. Absorption, light scattering and auto-
fluorescence are limitations to fluorescence imaging that
are significantly reduced in the NIR region (approximately
700 to 1000 nm). Biological chromophores, particularlyentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Structure of CANIR dye.
Figure 2 Characterization of the NIR Fluorescent HSA
Nanoparticles. (A,B) SEM image and hydrodynamic size histogram
of the NIR fluorescent HSA nanoparticles; (C,D) Normalized
absorbance and emission spectra of free CANIR dye (dotted lines)
and CANIR-HSA nanoparticles (solid lines), respectively.
Cohen and Margel Journal of Nanobiotechnology 2012, 10:36 Page 2 of 8
http://www.jnanobiotechnology.com/content/10/1/36hemoglobin, strongly absorb visible light, thereby limiting
the depth of penetration at shorter wavelengths to a few
millimeters. Other biological compounds such as water and
lipids strongly absorb light in the infrared region. In
addition, the decreased light scattering and autofluores-
cence in the NIR region provide the non-fluorescent back-
ground necessary for optimal detection of a fluorophore
within the surgical field [6,7]. Nanoparticle-based NIR
probes have been shown to have significant advantages over
free organic NIR dyes such as enhanced photostability and
biocompatibility, improved fluorescent signal (a large num-
ber of dye molecules per nanoparticle) and easy conjugation
of biomolecules to the nanoparticle surface functional
groups [8].
There is growing interest in the fabrication of albumin
nanoparticles due to their biocompatibility, biodegrad-
ability and non-antigenicity [9,10]. Albumin is one of the
most commonly used and characterized proteins in the
pharmaceutical field [11]. Soluble albumin and albumin
nanoparticles are currently used as a delivery vehicle in
chemotherapy as they are known to accumulate and to
be catabolized by cancerous tumors [12-14]. NIR dyes
such as Indocyanine Green (ICG) and other structurally
related cyanine dyes have been shown to have high affin-
ity to albumin [15]. Previous studies also showed that
the derivatization of cyanine dyes with carboxylic group/
s increases their binding affinity to albumin [16]. Encap-
sulation of dye molecules within the albumin matrix
plays a role in shielding the dye against reactive oxygen
species thereby reducing the risk of photobleaching.
In this work, we have exploited the high affinity of cya-
nine dyes to albumin for preparation of fluorescent NIR
albumin nanoparticles. The dye chosen for use throughout
this work is a previously synthesized carboxylic acid de-
rivative of the commercially available NIR dye IR-783
(CANIR, Figure 1). Leakage of the entrapped NIR dye into
PBS containing 4% albumin and into human bowel juice
was not detected. NIR fluorescent HSA nanoparticles were
bioactivated by covalently conjugating targeting agents
such as PNA, anti-CEA antibodies (anti-CEA) and anti-
TAG-72 antibodies (anti-TAG-72) to the nanoparticle sur-
face. These bioactive NIR fluorescent HSA nanoparticles
were found to specifically detect colon cancer tumors, as
demonstrated in vivo in a mouse model.
Results and discussion
Figure 2A&B show that the dry and hydrodynamic dia-
meters of the NIR fluorescent HSA nanoparticles used
in the present work are 100 ± 15 nm and 140 ± 15 nm,
respectively. The hydrodynamic diameter is higher than
that of the dry diameter since the hydrodynamic diam-
eter also takes into account the water molecules swol-
len within the nanoparticles as well as the water
molecules adsorbed on its surface [17]. In addition,Figure 2C&D illustrates that the maximum absorbance
of free CANIR and the NIR fluorescent HSA nanoparti-
cles occurs at approximately 790 and 810 nm, and the
maximum fluorescence emission intensity occurs at ap-
proximately 818 and 823 nm, respectively. The red-shift
of the NIR fluorescent HSA nanoparticles compared to
free CANIR dye is probably due to its physical binding
to the HSA that affects the dipole moment of the dye.
Leakage of the encapsulated CANIR dye into PBS dis-
persion in absence or presence of 4% soluble HSA was
not detected following ultrafiltration, as described in the
experimental section. There was also no leakage
observed when these fluorescent nanoparticles were dis-
persed in human bowel juice instead of PBS. These
results indicate that the CANIR is strongly associated
with the albumin nanoparticles, as already known from
Figure 3 Photostability of the CANIR-HSA nanoparticles (A) and
free CANIR (B) as a function of time. Samples of CANIR-HSA
nanoparticles and free CANIR were illuminated with a xenon flash
lamp for 20 min as described in the experimental part.
Figure 4 Color photographs and logarithmically scaled
fluorescent images of LS174t tumor cell line from a typical
orthotopic mouse model treated with PNA-conjugated NIR
fluorescent HSA nanoparticles. 6 mice were anesthetized and
treated with a 0.1% particle dispersion in PBS, via the anus. 20 min
later the colons were extensively washed with PBS and were then
allowed to recover for 1.5 h (A) and for 4 h (B). The colons were
then removed and treated as described in the experimental part.
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the continuous phase (PBS or bowl juice).
Optimization of the CANIR concentration entrapped
within the HSA nanoparticles
In order to optimize the fluorescence intensity of the
NIR fluorescent nanoparticles, different concentrations
of the CANIR dye were added to the 4% aqueous
HSA solution, followed by the formation of the fluor-
escent nanoparticles via the precipitation process
described in the experimental part. The concentration
of the entrapped CANIR dye that provided the max-
imum fluorescence intensity of the NIR fluorescent
HSA nanoparticles was 3.0 μg per 0.5 mg particles in
1 mL PBS. At higher dye concentrations, quenching of
fluorescence was observed, due to the short distance
between the dye molecules entrapped within the nano-
particles, leading to non-emissive energy transfer be-
tween them.
Photobleaching of the NIR fluorescent HSA nanoparticles
Photobleaching experiments were performed for free
CANIR dye and CANIR encapsulated within the HSA
nanoparticles, in order to examine their photostability.
Samples of the free CANIR dye and the CANIR en-
trapped HSA nanoparticles were illuminated at 800 nm
and their fluorescence intensities were measured. We
have demonstrated that, during illumination, the fluores-
cence intensity of the NIR fluorescent HSA nanoparti-
cles remains almost unaltered while that of the free
CANIR decreases significantly (Figure 3), which demon-
strates that the encapsulation of the CANIR within the
HSA nanoparticles reduces its photobleaching signifi-
cantly. The encapsulation of the dye probably protects
the dye against reactive oxygen species thereby reducing
the photobleaching [19].
In vivo optical imaging of human colon tumors in a
mouse model
For optimization of the tumor detection process, PNA
was covalently conjugated to the nanoparticles as
described in the experimental part. PNA binds to the
terminal sugar β-D-galactosyl-(1–3)-N-acetyl-D-galact-
osamine of the Thomsen-Friedenreich antigen [20]. In
vivo labeling of colonic neoplasms with PNA-conjugated
nanoparticles was performed using orthotopic mouse
model (6 mice) with colonic tumors originated from
LS174t cells injected to the colon wall 2 weeks before
the experiment. Mice were anesthetized and treated with
a 0.1% PNA-conjugated nanoparticles dispersion in PBS,
via the anus. 20 min later the colons were washed exten-
sively with PBS and allowed to recover for 1.5 h (3 mice)
and for 4 h (3 mice). The mouse colons were washed,
removed and rewashed, as described in the experimentalsection. A typical fluorescence imaging picture shown in
Figure 4A exhibits that after 1.5 h of recovery the tumor
as well as other parts of the colon were labeled by the
fluorescent PNA-conjugated nanoparticles. On the other
hand, Figure 4B exhibits that after 4 h of recovery the
tumors were specifically labeled with a high signal to
background ratio (SBR), the “background” referring to
the surrounding non-pathological tissue. These results
indicate that 4 h of recovery is essential in order to self-
Figure 5 Logarithmically scaled fluorescent and grayscale
images of typical LS174t (A) and HT29 (B) colon tumor cell lines
treated with non-conjugated (1) and anti-CEA (2) and anti-TAG-
72 (3) conjugated NIR fluorescent HSA nanoparticles: (4)
represents untreated tumor cell lines; (C) represents typical
colons of healthy mice treated with non-conjugated (1) and
anti-CEA (2) and anti-TAG-72 (3) conjugated NIR fluorescent
HSA nanoparticles. 44 mice (each set of experiment was done with
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nanoparticles, thereby increasing the SBR.
Similar mouse trials with 4 h recovery time were per-
formed with targeting agents other than PNA, e.g.,
monoclonal antibodies against CEA and against TAG-
72. For this purpose we conjugated these antibodies to
the NIR fluorescent albumin nanoparticles and tested4 mice) were anesthetized and treated with 0.1% particle dispersion
in PBS, via the anus. 20 min later the colons were extensively washed
with PBS and were then allowed to recover for 4 h. The colons were
then removed and treated as described in the experimental part.their efficiency for tumor detection in LS174t and HT29
colorectal cancer cell lines. CEA, a highly glycosylated
glycoprotein, and TAG-72, a human mucin (MUC1)-like
glycoprotein complex, are both highly expressed in most
human carcinomas, and therefore used as biomarkers in
several modalities of human carcinoma [21-23]. Tumors
originating from HT29 cell line serve as a negative con-
trol since this cell-line expresses the CEA and TAG-72
antigens to a much lower extent, at least 103 times,
lower than the LS174t cell-line [24,25].
Figure 5 shows fluorescent and grayscale images of
LS174t (A) and HT29 (B) colon tumor cell lines treated
with non-conjugated (1) and anti-CEA (2) and anti-
TAG-72 (3) conjugated NIR fluorescent HSA nanoparti-
cles. This Figure clearly illustrates that the non-
conjugated nanoparticles did not detect the tumors of
both LS174t and HT29 cell lines. On the other hand, the
anti-CEA and anti-TAG-72-conjugated nanoparticles se-
lectively labeled the LS174t tumor with very high SBR
(40–50), but did not significantly label the HT29 tumors,
as expected. These results are probably due to the sig-
nificant difference in the concentration of the CEA and
TAG-72 receptors on these cell lines, as mentioned pre-
viously. In addition, Figure 5C illustrates that the anti-
CEA and anti-TAG-72-conjugated NIR fluorescent HSA
nanoparticles did not label the colons of the healthy
mice. Also, Figure 5A4 and 5B4 indicate that under the
experimental conditions the autofluorescence signal of
the non-treated tumor cell lines is negligible.
We should also note that the mouse colon treated
with the anti-TAG-72-conjugated fluorescent HSA
nanoparticles shown in Figure 5A3 has two clear fluores-
cent signals (both with a SBR of approximately 50). The
tumor in the distal part of the colon is visible to the eye,
whereas the more proximal fluorescent signal was only
revealed as pathological subsequent to histological ana-
lysis. This result may suggest a significant advantage of
NIR fluorescence imaging using NIR fluorescent nano-
particles, over regular colonoscopy.
It should be noted that most tumors developed in the
mouse colons in the orthotopic model used were exposed
to the colon lumen. However, infrequently tumors grew
Figure 7 SEM images of sections from LS174t tumor implants
of a mouse colon untreated (A) and treated (B) with the anti-
CEA-conjugated NIR fluorescent HSA nanoparticles.
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Figure 6 exhibits for example the histological analysis of
lumen-exposed (Figure 6A) and lumen-not exposed
(Figure 6B) tumors. It seems that our biomolecule-
conjugated NIR fluorescent HSA nanoparticles detect
specifically the tumors exposed to the lumen and not
those not exposed to the colon lumen.
In order to prove that the bioactivated NIR fluorescent
HSA nanoparticles are indeed responsible for the fluores-
cent signal observed, tumor sections were also analyzed
by SEM as shown in Figure 7. This figure illustrates that
the section belonging to the untreated tumor does not
contain nanoparticles (Figure 7A), whereas the treated
tumors contain observable nanoparticles.
Conclusions
The NIR fluorescent HSA nanoparticles discussed in this
work have the potential to assist in early diagnosis of co-
lonic neoplasms. The PNA, anti-CEA and anti-TAG-72-
conjugated nanoparticles specifically label in vivo the
mice colon tumor tissues. While detection of cancer by
these bioactivated nanoparticles has been demonstrated,
the conjugation of a few targeting agents is likely to sig-
nificantly enhance the fluorescent signal and the specifi-
city, and therefore enhance their efficiency as diagnostic
biomaterials.
In future work, the particles could be used for in vivo
detection using either whole body fluorescence imaging
or a newly developed fluorescent endoscopy camera. We
plan to extend this study to include additional tumor-
targeting ligands including antibodies, proteins and
small peptides such as epidermal growth factor (EGF)
and TRAIL [26,27]. In addition, cancer drugs such as
paclitaxel and doxorubicin may also be encapsulated
within these NIR fluorescent HSA nanoparticles, so that




The following analytical-grade chemicals were pur-
chased from commercial sources and were used withoutFigure 6 Histological analysis (H&E staining) of lumen-facing
(A) and non-lumen-facing (B) tumors treated with anti-CEA-
conjugated NIR fluorescent HSA nanoparticles.further purification: 2-[2-[2-Chloro-3-[2-[1,3-dihydro-3,
3-dimethyl-1-(4-sulfobutyl)-2 H-indol-2-ylidene]ethylidene]-
1 cyclohexen-1-yl]ethenyl]-3,3-dimethyl-1-(4-sulfobutyl)-3
H-indolium inner salt sodium salt (IR-783), HSA, 4-
mercaptobenzoic acid, N,N-dimethylformamide (DMF),
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC),
sepharose 4B, peanut agglutinin (PNA) and fluorescein
isothiocyanate-conjugated peanut agglutinin (FITC-PNA),
hematoxylin and eosin from Sigma (Rehovot, Israel); N-
hydroxysulfosuccinimide (Sulfo-NHS) from Thermo Sci-
entific, U.S.A; 2-morpholino ethanesulfonic acid (MES,
pH 6) from Fisher Scientific, U.S.A; Tissue-TekW O.C.T.
from Sakura, Japan. Phosphate Buffered Saline (PBS),
Minimum Essential Medium (MEM) eagle, McCoy's 5A
medium and Dulbecco's modification of eagle's medium
(DMEM), glutamine, penicillin and streptomycin from
Bet Haemek, Israel; LS174t and HT29 tumor cell lines
from American Type Culture Collection (ATCC); mono-
clonal anti-CEA (T86-66) and anti-TAG-72 (CC-49)
antibodies were purified from the hybridoma supernatant
at Alomone Labs, Israel; human bowel juice were
obtained from Prof. A. Nissan, Surgery Department,
Rabin Medical Center, Beilinson Hospital, Israel. Water
was purified by passing deionized water through an Elga-
stat Spectrum reverse osmosis system (Elga Ltd., High
Wycombe, UK).Synthesis of the NIR fluorescent CANIR dye
CANIR (Figure 1) was prepared by interacting the com-
mercially available IR-783 with 4-mercaptobenzoic acid,
as described by Strekowski et al. [28]. Briefly, IR-783
(250 mg, 0.33 mmol) and 4-mercaptobenzoic acid
(154 mg, 1 mmol) were dissolved in 10 mL DMF. This
solution was stirred overnight at room temperature. A
mixture of EtOH/ether (1:20, 20 mL) was added drop-
wise and the dark precipitate was separated by centrifu-
gation, washed with ether and lyophilized. The structure
and purity (99%) was confirmed by elemental analysis,
MS and 1H and 13 C NMR.
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The NIR fluorescent HSA nanoparticles were prepared
by a desolvation technique via a precipitation process
[29,30]. Briefly, ethanol (12.5 mL) was added to an aque-
ous solution (6.25 mL) of HSA (250 mg) and CANIR
(1.25 mg). The obtained solution was then stirred at
room temperature for 15 min at 800 rpm. Then, the
temperature was raised to 70°C and the mixture was
stirred for additional 4 h, followed by 78°C for 12 h. The
obtained NIR fluorescent particles dispersed in water
were then washed from impurities by sepharose 4B gel
filtration.
Non-fluorescent HSA nanoparticles were prepared
similarly to those of the NIR fluorescent HSA nanoparti-
cles, in the absence of the CANIR dye.
Determination of the encapsulated CANIR concentration
in the NIR fluorescent HSA nanoparticles
The concentration of the encapsulated CANIR was
determined for 0.5 mg/mL nanoparticles, via a calibra-
tion curve obtained by measuring the integral of absorb-
ance peaks of standard solutions of free CANIR in PBS
(at wavelengths 630 – 900 nm).
Optimization of the CANIR concentration encapsulated
within the HSA nanoparticles
Different concentrations of the CANIR dye were added
to the 4% aqueous HSA solution (weight % ratio of the
CANIR dye and the NIR fluorescent HSA nanoparticles
were 0.1, 0.25, 0.5, 0.7 and 1), followed by the formation
of the fluorescent nanoparticles. The NIR fluorescent
HSA nanoparticles dispersed in PBS were diluted with
PBS to 0.5 mg/mL and their fluorescence intensities at
823 nm were then measured.
Leakage extent of the CANIR encapsulated in the
fluorescent HSA nanoparticles into PBS and human bowel
juice
4% HSA solution in PBS containing the NIR fluorescent
HSA nanoparticle (1 mg/mL) was shaken at 37°C for 4 h
and then filtered via a 300-kDa filtration tube (VS0241
VIVA SPIN) at 4000 rpm. The fluorescence intensity of
the supernatant was then measured at 750 nm. A similar
procedure was performed with human bowel juice as a
continuous phase substituting the 4% HSA solution in
PBS.
Conjugation of the tumor-targeting ligands (PNA,
anti-CEA and anti-TAG-72) to the NIR fluorescent HSA
nanoparticles
PNA was covalently conjugated to the nanoparticle sur-
face carboxylate groups via the cabodiimide activation
method [31]. Briefly, EDC (1 mg) and Sulfo-NHS (1 mg)
were each dissolved in 0.1 M MES (pH 6.0, 1 mL)containing 0.5 M NaCl. The EDC solution (1 mg/mL, 10
μL) was added to an aqueous solution of PNA (0.25 mg,
62.5 μL), followed by the addition of the sulfo-NHS solu-
tion (1 mg/mL, 25 μL). The mixture was then shaken at
room temperature for 15 min, followed by the addition
of the NIR fluorescent HSA nanoparticles (2.5 mg, 1 mL
PBS). The mixture was then shaken for an additional
90 min. The obtained PNA-conjugated fluorescent nano-
particles were then washed from excess reagents by
sepharose 4B gel filtration. FITC-PNA, anti-CEA and
anti-TAG-72 were conjugated to the NIR fluorescent
HSA nanoparticles via a similar procedure substituting
the PNA by the other bioactive reagents. The concentra-
tion of bound PNA (2.4 μg/mg nanoparticles) was deter-
mined with FITC-PNA via a calibration curve of FITC.
The concentration of bound anti-CEA and anti-TAG-72
(2.2 ± 0.2 μg/mg nanoparticles) were determined by
ELISA.Characterization of the NIR fluorescent HSA nanoparticles
Particle size and size distribution were determined by
DLS with photon cross-correlation spectroscopy (Nano-
phox particle analyzer, Sympatec GmbH, Germany) and
by Scanning Electron Microscopy (SEM) (JEOL, JSM-
840 Model, Japan). For the SEM study, the diameter of
more than 100 particles was measured with the image
analysis software AnalySIS Auto (Soft Imaging Sys-
temGmbH, Germany).
Fluorescence measurements of the FITC-PNA were
performed using a multiplate reader TECAN Spectra-
Fluor Plus (Neotec Scientific Instruments) with excita-
tion wavelength of 485 ± 10 nm and emission
wavelength of 535 ± 10 nm, integration time was 40 μs
and gain was set to 70.
Fluorescence spectra of the non-conjugated and bio-
active conjugated NIR fluorescent HSA nanoparticles
were recorded using a spectrofluorometer (Cary eclipse,
Agilent Technologies Inc.). Excitation and emission slits
were fixed at 5 nm, and λex was set at 750 nm. For
photobleaching experiments, the samples were diluted
to 0.05 M and λex was set at 800 nm and λem at 830 nm.
Each of the samples was illuminated continuously, and
fluorescence intensity was measured over a period of
20 min. The intensity values were normalized.Cell lines
Human colorectal adenocarcinoma cell lines were used
for each of the experiments. The LS174t cell line was
maintained in Minimum Essential Medium (MEM) eagle
supplemented with heat-inactivated FBS (10%), penicillin
(100 IU/mL), streptomycin (100 μg/mL) and l-glutamine
(2 mM). The HT29 cell line was maintained in McCoy’s
5A medium supplemented with FBS (10%), penicillin
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(2 mM).
Detecting of human colon tumor with the non-
conjugated and bioactive- conjugated NIR fluorescent
HSA nanoparticles in a mouse model
Experiments were performed according to protocols of
the Israeli National Council for Animal Experiments by
Harlan Biotech, Israel. Cancerous cells (30 uL containing
2x106 LS174t or HT29 cells) were injected into the
mouse intestinal wall. 2 weeks later the nude mice (50
mice) were anaesthetized and treated with non-
conjugated and bioactive-conjugated NIR fluorescent
HSA nanoparticles (0.1%, 200 μL), via the anus, using
guidance of a mini-colonoscope. 20 min later each colon
was washed with PBS (5 x 1 mL) and mice were allowed
to recover for 4 h. The mice were sacrificed and the
colons were removed. Each colon was spread on a solid
surface, and imaging was performed by using the Odys-
seyW Infrared Imaging System, (Li-Cor Biosciences, Lin-
coln, NE, USA) with excitation wavelength 780 nm and
emission wavelength 800 nm.
Histological analysis
Following the in vivo mice experiments the tissues were
frozen in liquid nitrogen in Tissue-TekW O.C.T. com-
pound and cryosectioned at 5 microns in the cryostat.
The sections were picked up on a glass slide and stained
with hematoxylin and eosin (H&E) for histopathological
examination. The sections were also spread on a stab,
stained with H&E and visualized by SEM.
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